<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nanoviricides, Inc. — News on 6ix</title>
<link>https://6ix.com/company/nanoviricides-inc</link>
<description>Latest news and press releases for Nanoviricides, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nanoviricides-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7714751cc36e47533df1a.webp</url>
<title>Nanoviricides, Inc.</title>
<link>https://6ix.com/company/nanoviricides-inc</link>
</image>
<item>
<title>Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides</title>
<link>https://6ix.com/company/nanoviricides-inc/news/measles-rare-pediatric-disease-drug-designation-application-filed-for-nv-387-prv-provides-for-strong-business-case-says-nanoviricides</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/measles-rare-pediatric-disease-drug-designation-application-filed-for-nv-387-prv-provides-for-strong-business-case-says-nanoviricides</guid>
<pubDate>Tue, 07 Apr 2026 12:30:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...</description>
</item>
<item>
<title>Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides</title>
<link>https://6ix.com/company/nanoviricides-inc/news/phase-ii-clinical-trial-of-monkeypox-treatment-by-nv-387-to-commence-soon-announces-nanoviricides</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/phase-ii-clinical-trial-of-monkeypox-treatment-by-nv-387-to-commence-soon-announces-nanoviricides</guid>
<pubDate>Wed, 01 Apr 2026 12:30:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo ...</description>
</item>
<item>
<title>NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-presenting-at-nibas-152nd-investment-conference-in-fort-lauderdale-fl-march-12-2026-announces-manufacture-of-phase-ii-clinical-product-nv-387-oral-gummies-is-complete</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-presenting-at-nibas-152nd-investment-conference-in-fort-lauderdale-fl-march-12-2026-announces-manufacture-of-phase-ii-clinical-product-nv-387-oral-gummies-is-complete</guid>
<pubDate>Wed, 11 Mar 2026 12:30:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be ...</description>
</item>
<item>
<title>MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides</title>
<link>https://6ix.com/company/nanoviricides-inc/news/mpox-orphan-drug-designation-application-filed-for-nv-387-declares-nanoviricides</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/mpox-orphan-drug-designation-application-filed-for-nv-387-declares-nanoviricides</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on ...</description>
</item>
<item>
<title>Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides</title>
<link>https://6ix.com/company/nanoviricides-inc/news/measles-orphan-drug-designation-application-filed-for-nv-387-declares-nanoviricides</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/measles-orphan-drug-designation-application-filed-for-nv-387-declares-nanoviricides</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on ...</description>
</item>
<item>
<title>NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-3rd-annual-dealflow-discovery-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-3rd-annual-dealflow-discovery-conference</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will participate ...</description>
</item>
<item>
<title>NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-comments-on-the-need-for-broad-spectrum-antivirals-in-light-of-the-current-influenza-wave-nv-387-is-effective-against-h3n2</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-comments-on-the-need-for-broad-spectrum-antivirals-in-light-of-the-current-influenza-wave-nv-387-is-effective-against-h3n2</guid>
<pubDate>Tue, 13 Jan 2026 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, declares that the current ...</description>
</item>
<item>
<title>NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-has-signed-a-master-services-agreement-with-onlyorphanscote-regarding-orphan-drug-strategy-of-nv-387-for-treatment-of-mpox-smallpox-and-measles</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-has-signed-a-master-services-agreement-with-onlyorphanscote-regarding-orphan-drug-strategy-of-nv-387-for-treatment-of-mpox-smallpox-and-measles</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...</description>
</item>
<item>
<title>NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-inc-has-filed-its-quarterly-report-subsequent-raise-has-fortified-fiscal-position</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-inc-has-filed-its-quarterly-report-subsequent-raise-has-fortified-fiscal-position</guid>
<pubDate>Mon, 17 Nov 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and ...</description>
</item>
<item>
<title>NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-pharma-partnering-summit-2025-in-boston-today-november-14th-nv-387-is-effective-against-h3n2</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-pharma-partnering-summit-2025-in-boston-today-november-14th-nv-387-is-effective-against-h3n2</guid>
<pubDate>Fri, 14 Nov 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it ...</description>
</item>
<item>
<title>NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-announces-closing-of-dollar6-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-close</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-announces-closing-of-dollar6-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-close</guid>
<pubDate>Wed, 12 Nov 2025 22:01:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement with a single healthcare institutional investor ...</description>
</item>
<item>
<title>NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-announces-pricing-of-dollar6-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-close</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-announces-pricing-of-dollar6-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-close</guid>
<pubDate>Tue, 11 Nov 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare institutional investor for the ...</description>
</item>
<item>
<title>NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-has-received-approval-to-start-phase-ii-clinical-trial-of-nv-387-for-the-treatment-of-mpox-by-the-regulatory-agency-acorep-of-the-democratic-republic-of-congo</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-has-received-approval-to-start-phase-ii-clinical-trial-of-nv-387-for-the-treatment-of-mpox-by-the-regulatory-agency-acorep-of-the-democratic-republic-of-congo</guid>
<pubDate>Mon, 10 Nov 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory ...</description>
</item>
<item>
<title>NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-annual-shareholders-meeting-to-be-held-at-10-am-on-saturday-november-5th-at-on-saturday-november-8-2025-at-the-hampton-inn-and-suites-stamford-ct</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-annual-shareholders-meeting-to-be-held-at-10-am-on-saturday-november-5th-at-on-saturday-november-8-2025-at-the-hampton-inn-and-suites-stamford-ct</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary ...</description>
</item>
<item>
<title>NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-spartan-capital-investor-conference-2025-in-new-york-city-today-november-3rd</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-spartan-capital-investor-conference-2025-in-new-york-city-today-november-3rd</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will ...</description>
</item>
<item>
<title>NanoViricides to Present at the PODD 2025 Conference in Boston on October 27</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-podd-2025-conference-in-boston-on-october-27</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-to-present-at-the-podd-2025-conference-in-boston-on-october-27</guid>
<pubDate>Mon, 27 Oct 2025 12:45:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...</description>
</item>
<item>
<title>In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides</title>
<link>https://6ix.com/company/nanoviricides-inc/news/in-treating-measles-infection-nv-387-showed-strong-antiviral-activity-and-significantly-protected-lungs-from-damage-describes-nanoviricides</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/in-treating-measles-infection-nv-387-showed-strong-antiviral-activity-and-significantly-protected-lungs-from-damage-describes-nanoviricides</guid>
<pubDate>Wed, 22 Oct 2025 12:45:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in cell culture ...</description>
</item>
<item>
<title>A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus</title>
<link>https://6ix.com/company/nanoviricides-inc/news/a-measles-drug-with-strong-activity-without-toxicity-can-be-available-now-for-emergency-use-says-nanoviricides-nv-387-broad-spectrum-antiviral-with-activity-against-measles-virus</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/a-measles-drug-with-strong-activity-without-toxicity-can-be-available-now-for-emergency-use-says-nanoviricides-nv-387-broad-spectrum-antiviral-with-activity-against-measles-virus</guid>
<pubDate>Mon, 20 Oct 2025 12:45:00 GMT</pubDate>
<description>SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized ...</description>
</item>
<item>
<title>NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-dual-track-clinical-strategy-explained-by-a-research-report-broad-spectrum-antiviral-nv-387-at-phase-ii-clinical-trial-stage-for-mpox-and-also-for-acute-respiratory-infections-of-all-viruses</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-dual-track-clinical-strategy-explained-by-a-research-report-broad-spectrum-antiviral-nv-387-at-phase-ii-clinical-trial-stage-for-mpox-and-also-for-acute-respiratory-infections-of-all-viruses</guid>
<pubDate>Wed, 15 Oct 2025 12:45:00 GMT</pubDate>
<description>SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains its dual-track, rapid clinical development strategy ...</description>
</item>
<item>
<title>NanoViricides, Inc. Has Filed its Annual Report</title>
<link>https://6ix.com/company/nanoviricides-inc/news/nanoviricides-inc-has-filed-its-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/nanoviricides-inc/news/nanoviricides-inc-has-filed-its-annual-report</guid>
<pubDate>Tue, 30 Sep 2025 12:45:00 GMT</pubDate>
<description>Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) ...</description>
</item>
</channel>
</rss>